The Neutrophil-to-Albumin Ratio (NAR): A Novel Index in Relation to Clinical Symptoms, Quality of Life, and Psychological Status in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Xijing Huang,An Li,Ping Long,Ya Liu,Zhou Zhou,Yan Pan
DOI: https://doi.org/10.2147/jir.s458363
IF: 4.5
2024-06-11
Journal of Inflammation Research
Abstract:Xijing Huang, 1, 2, &ast An Li, 1, 2, &ast Ping Long, 1, 2, &ast Ya Liu, 1 Zhou Zhou, 1 Yan Pan 1 1 Department of Gastroenterology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, People's Republic of China; 2 Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yan Pan, Email Introduction: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder characterized by chronic abdominal pain and alterations in bowel habits. Despite the importance of biomarkers in disease management, the quest for precise and non-invasive biomarkers for IBS continues. Methods: This study focuses on investigating the clinical significance of the neutrophil-to-albumin ratio (NAR) as a potential biomarker in IBS. A cohort of 86 patients diagnosed with diarrhea-predominant IBS (IBS-D) and 106 healthy individuals were assessed for clinical symptoms, quality of life (QOL), psychological status, as well as serum and mucosal cytokine production. Results: Our findings revealed that NAR levels were notably elevated in patients with IBS-D compared to healthy controls. Positive correlations were observed between NAR levels and IBS clinical symptoms, while negative correlations were noted with QOL. Additionally, NAR showed positive associations with anxiety and depression scores, along with significant relationships with cytokine production (serum IL-6, TNF-α, IL-1β, IL-17A, GM-CSF, IFN-γ, MCP-1; mucosal IL-6, TNF-α, IL-1β, IL-17A) in IBS-D. Interestingly, patients with lower baseline NAR levels demonstrated potentially better clinical outcomes. Conclusion: The study underscores the potential utility of NAR as a novel biomarker in IBS, emphasizing its role in enhancing disease monitoring, understanding disease pathophysiology, and tailoring treatment strategies for patients with IBS-D. Keywords: irritable bowel syndrome, the neutrophil-to-albumin ratio, biomarkers, inflammation Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by chronic abdominal pain and alterations in bowel habits. It affects a significant portion of the population worldwide, making it a significant health concern. 1 The exact etiology of IBS remains unclear, but it is believed to involve complex interactions between genetic, environmental, and psychosocial factors. Clinically, IBS is diagnosed based on the presence of characteristic symptoms, including abdominal pain or discomfort, bloating, and changes in bowel habits such as diarrhea, constipation, or a combination of both. 2 However, the diagnosis of IBS is challenging due to the absence of specific diagnostic markers or identifiable structural abnormalities in the gastrointestinal tract. 3 This lack of objective diagnostic criteria often leads to delays in diagnosis and misclassification of patients with other gastrointestinal disorders. Additionally, monitoring disease activity and treatment response in IBS poses further challenges. Traditionally, clinical symptoms and patient-reported outcomes have been used to assess disease activity and treatment response. However, these subjective measures can be influenced by various factors, leading to difficulties in accurately evaluating disease severity and predicting treatment outcomes. 3–5 As a result, there is a need for objective and reliable biomarkers that can aid in the diagnosis, monitoring, and management of IBS. A biomarker for IBS is crucial as it can offer objective measures to aid in the accurate diagnosis, prognosis, and monitoring of the condition, which is particularly challenging due to its multifactorial nature and subjective symptomatology. Having a reliable biomarker can help improve patient outcomes, guide personalized treatment strategies, and enhance our understanding of the underlying pathophysiology of IBS. Several biomarkers have been investigated in the clinical management of IBS. However, the development of precise, feasible, and non-invasive biomarkers for IBS is still an ongoing research area. 6 Peripheral blood-based biomarker research has made significant progress in various diseases. The neutrophil-to-albumin ratio (NAR) has garnered attention as a valuable marker of systemic inflammation in various medical conditions, including inflammatory diseases, vascular disorders, and cancers. 7–11 Combining blood -Abstract Truncated-
immunology
What problem does this paper attempt to address?